Why Did You Stop Losing Weight on Semaglutide? A Chattanooga Guide
I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.
You started semaglutide here in Chattanooga, the weight came off steadily for a few months, and then it just stopped. Not slowed — stopped. You’re still taking the same dose, still doing what you were doing, and the scale hasn’t moved in weeks. If you’re searching “why did I stop losing weight on semaglutide,” you’re not imagining it, and you didn’t do anything wrong. A plateau is physiology, not failure. The question is what’s actually causing yours, and that requires someone looking at your chart — not a general answer that fits everyone.
Your body does not want to stay at a lower weight. That’s not a character flaw, it’s a survival mechanism. As you lose weight, your metabolism adjusts downward — you burn fewer calories at rest than someone who started at your new, lower weight naturally would. Your hunger hormones shift too, working against continued loss. This is called metabolic adaptation, and it happens to almost everyone who loses a meaningful amount of weight, medication or not.
Semaglutide works by acting on GLP-1 receptors to reduce appetite and slow gastric emptying. It doesn’t turn off metabolic adaptation — it works alongside your biology, not against it. When the two forces meet in the middle, the scale stalls. That’s not the drug failing. That’s your body doing exactly what bodies do.
The STEP 1 trial (Wilding et al., NEJM, 2021) reported a mean weight loss of 14.9% of body weight at 68 weeks on semaglutide. Read that sentence carefully: it’s a mean, not a guarantee. Half the trial population lost more than that, and half lost less. Individual trajectories inside that average were not straight lines — they climbed, flattened, sometimes climbed again.
A plateau partway through is inside the expected pattern, not outside it. What the trial data can’t tell you is why your specific plateau is happening — whether it’s the normal mid-course flattening most patients experience, or something that needs an actual adjustment. That distinction only shows up in a chart review, not a study average.
A handful of things drive most plateaus, and they’re rarely just one thing in isolation:
Metabolic adaptation. Covered above — expected, and it’s the most common driver of a true plateau once the initial weight loss phase has run its course.
Incomplete titration. If you’re still on a starting or mid-range dose, you may not yet be at the dose where semaglutide’s appetite effect fully kicks in for you. Dose escalation is deliberately gradual for safety and tolerability — but “gradual” and “stalled at too low a dose for you” can look identical from the outside. Only a provider who knows your titration history can tell the difference.
Diet drift. As appetite drops, it’s common to eat less of everything, protein included, and to lose muscle along with fat. Less muscle means a lower resting metabolic rate, which can flatten the scale even while body composition is still improving.
Adherence gaps. Missed doses, inconsistent injection timing, or unintentionally spacing doses further apart than prescribed all blunt the medication’s effect without you necessarily noticing.
The scale itself. Water retention, hormonal cycles, and muscle gain from added activity can mask real fat loss for weeks at a time. The scale is one data point, not the whole picture.
Any of these can produce the exact same symptom — a stalled number — with completely different fixes. That’s the trap of generic advice: it treats every plateau as the same plateau.
If a true plateau persists despite being at a full, well-tolerated dose of semaglutide, with diet and adherence accounted for, the next step is a real clinical decision, not a guess. Sometimes the answer is a dose increase within semaglutide’s range. Sometimes it’s holding the current dose longer to let your body adjust before pushing further — patience the plateau, rather than chase it. And sometimes, when semaglutide’s GLP-1 mechanism alone has plateaued a patient who’s done everything right, the next tool is different, not just more.
Tirzepatide adds a second mechanism — GIP receptor activity alongside GLP-1 — and the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed weight loss up to 22.5% at 72 weeks in patients on the higher dose. That’s not a reason to DIY-switch yourself. It’s a reason to have a physician-guided escalation conversation, because tirzepatide comes with its own titration schedule, its own side-effect profile, and its own reasons it might or might not be right for your specific case. A drug swap decided by a form is a guess. A drug swap decided after a chart review is medicine.
Here’s the honest problem with most GLP-1 telehealth platforms: they can re-ship you the same dose. That’s the extent of what an algorithm-driven queue can do when the scale stops moving. Ro, Hims/Hers, Henry Meds, Found — none of these are physician-led platforms, and none of them have someone looking at your actual titration history, your labs, or your specific pattern of loss and stall before renewing your prescription. A plateau that needs real judgment gets the same refill a plateau that’s still improving gets.
I’m a board-certified family medicine physician, and I work ER shifts — which means I’ve also seen what happens when a medication is managed by a subscription calendar instead of a person paying attention. At Summit, I personally review every chart myself, from Chattanooga, for patients here. When you plateau, I’m looking at your actual dosing history, how fast you climbed, how you’ve tolerated each step, and your labs — not running a script that assumes every patient’s stall looks the same. A plateau that’s a normal pause gets a different answer than a plateau that’s a true ceiling on the current approach, and the only way to tell them apart is a physician actually looking.
If your weight loss on semaglutide has stalled, don’t wait it out blind, and don’t guess at a fix from a forum thread. Log your current dose, how long you’ve been at it, and roughly when the scale stopped moving, and bring that to your next visit. That’s the information that turns “I don’t know why this stopped working” into an actual plan — whether that plan is patience, a dose adjustment, or a conversation about tirzepatide.
A plateau on semaglutide is not the end of your progress. It’s a signal that your case needs a closer look, not a louder version of the same approach. That’s what a real chart review is for, and it’s the difference between a program that reacts to your plateau and one that just keeps shipping the same vial. For more on the biology, dosing, and what to expect at each stage, the Summit blog has the full library.
Ready to start? Apply at summitmetabolichealth.com/apply.
This post is educational and does not replace individualized medical advice. Talk to your provider before changing your dose or medication.
